VISISURE
DEAD

Serial Number

79255177

Owner

NOVARTIS AG

Attorney

Maury M. Tepper, III

Filing Date

Jan 16, 2019

Add to watchlist:

No watchlists yet
View on USPTO

VISISURE Trademark

Serial Number: 79255177 • Registration: 5876871

VISISURE is a trademark filed by NOVARTIS AG on January 16, 2019. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). The application is currently no longer active.

Owner Contact Info

NOVARTIS AG (7,171 trademarks)

CH-4002
BASEL , CH

Entity Type: 03

Trademark Details

Filing Date

January 16, 2019

Registration Date

October 8, 2019

Published for Opposition

July 23, 2019

Cancellation Date

February 18, 2025

Goods & Services

Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and the treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma

Medical injection devices sold empty

Filing History

NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Mar 8, 2025 DENA
DEATH OF INTERNATIONAL REGISTRATION
Mar 8, 2025 DETH
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Oct 8, 2024 REM3
FINAL DECISION TRANSACTION PROCESSED BY IB
Feb 21, 2020 FINV
FINAL DISPOSITION NOTICE SENT TO IB
Feb 4, 2020 FICS
FINAL DISPOSITION PROCESSED
Feb 4, 2020 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jan 8, 2020 FICR
REGISTERED-PRINCIPAL REGISTER
Oct 8, 2019 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 23, 2019 NPUB
PUBLISHED FOR OPPOSITION
Jul 23, 2019 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 3, 2019 NONP
ASSIGNED TO LIE
Jun 19, 2019 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 7, 2019 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 6, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 5, 2019 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 5, 2019 TROA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jun 4, 2019 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jun 4, 2019 REAP
REFUSAL PROCESSED BY IB
May 18, 2019 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
May 1, 2019 RFCS
REFUSAL PROCESSED BY MPU
May 1, 2019 RFRR
APPLICATION FILING RECEIPT MAILED
Apr 9, 2019 MAFR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Apr 5, 2019 RFCR
NON-FINAL ACTION WRITTEN
Apr 4, 2019 CNRT
ASSIGNED TO EXAMINER
Apr 3, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 3, 2019 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Apr 2, 2019 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 28, 2019 REPR